Boundless Bio, Inc. BOLD

BOLD Company Overview

Boundless Bio, Inc. is a U.S.-based clinical-stage oncology biotechnology company focused on developing therapies that target extrachromosomal DNA (ecDNA), a genomic driver associated with aggressive cancers, therapeutic resistance, and poor clinical outcomes. The company operates within the biotechnology and precision oncology industries, with research centered on identifying and exploiting vulnerabilities unique to ecDNA-positive tumors. Boundless Bio’s core business is the discovery and development of small-molecule therapeutics designed to inhibit pathways that ecDNA-dependent cancers require for survival and proliferation.

The company’s primary revenue sources have historically consisted of collaboration revenue and financing activities, as it remains in the clinical development stage and has not reported commercial product sales. Its lead programs include ecDNA-directed therapeutic candidates targeting DNA damage response and replication stress pathways. Boundless Bio positions itself as one of the first companies specifically dedicated to ecDNA biology as a therapeutic area, supported by proprietary research platforms and translational diagnostics capabilities. The company was founded in 2018 and emerged from academic research associated with cancer genomics and ecDNA biology discoveries. It later completed an initial public offering on the Nasdaq under the ticker BOLD.